Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ranizurel
- Development stage
- Phase 4
- Lead developer
- Reliance Life Sciences
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravitreal
01
Overview
Ranizurel is a biosimilar of ranibizumab, a recombinant humanized IgG1 kappa isotype monoclonal antibody fragment that selectively binds to and inhibits the biological activity of human vascular endothelial growth factor A (VEGF-A). By blocking VEGF-A, it prevents abnormal blood vessel growth and leakage in the eye. This mechanism helps treat vision loss associated with neovascular (wet) age-related macular degeneration (AMD), diabetic macular edema, diabetic retinopathy, myopic choroidal neovascularization (mCNV), and macular edema following retinal vein occlusion. Ranizurel is administered as an intravitreal injection by an ophthalmologist[2][5][8].
- Brand names
- RanizuRel
- Other names
- ranibizumab biosimilarRanizuRel
02
Targets
Beyond the preview
Go deeper on ranizurel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ranizurel.